ReviewCancers2023
Malignant Peritoneal Mesothelioma: An In-Depth and Up-to-Date Review of Pathogenesis, Diagnosis, Management and Future Directions.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma.NPJ precision oncology · 2026Article
- Article
- Assessing the Annual Risk of Recurrence Following Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Diffuse Malignant Peritoneal Mesothelioma Patients.Annals of surgical oncology · 2025Article
- Use of Neoadjuvant Immunotherapy in Malignant Peritoneal Mesothelioma as a Bridge to Surgical Intervention: A Case Report.The American journal of case reports · 2025Article
- Dynamic evolution of NK cells and immune remodeling mediated by CRS + HIPEC: prognostic mechanisms and therapeutic implications for malignant peritoneal mesothelioma.World journal of surgical oncology · 2025Article
- A rare presentation of peritoneal mesothelioma: Esophageal encasement and Sister Mary Joseph nodule.Radiology case reports · 2025Article
- Atypical abdominal pain: uncovering malignant peritoneal mesothelioma in suspected Crohn's disease: a case report.Journal of gastrointestinal oncology · 2025Article
- Non-Asbestos-Related Malignant Peritoneal Mesothelioma: A Diagnostic Challenge in a Case of Unexplained Ascites.Cureus · 2025Article
- Loss of MTAP expression is not an accurate surrogate for CDKN2A homozygous deletions in peritoneal mesothelioma.Histopathology · 2025Article
- Peritoneal Mesothelioma in a Patient with Long-Standing Crohn's Disease: Cause or Coincidence?GE Portuguese journal of gastroenterology · 2025Article
- Long-term survival in peritoneal mesothelioma treated with 24 consecutive PIPACs.Pleura and peritoneum · 2025Article
- Oncologic outcomes and predictors of recurrence following minimally invasive and open surgery for thymoma.Journal of thoracic disease · 2025Article
- Article
- Analysis of TERT mRNA Levels and Clinicopathological Features in Patients with Peritoneal Mesothelioma.Cancers · 2025Article
- Mortality rate for mesothelioma as a basic cause in the period 2017-2022 in Chile.Ecancermedicalscience · 2025Article
- Capsaicin Exerts Antitumor Activity in Mesothelioma Cells.Nutrients · 2024Article
- ED diagnosis of peritoneal carcinomatosis.Emergency radiology · 2024Article
- Incidental Diagnosis of Malignant Peritoneal Mesothelioma During Liver Transplantation Surgery: A Case Report.The American journal of case reports · 2024Article
- Implementation of a high-resolution, high-contrast magnetic resonance imaging protocol with extended delayed phases for peritoneal mesothelioma.Quantitative imaging in medicine and surgery · 2024Article
- Malignant Mesothelioma Extending from Peritoneum to Pleura: A Diagnostic Challenge and Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant peritoneal mesothelioma (MPM) is an extremely rare malignancy usually confined to the abdominal cavity. With an aggressive natural history, morbidity and mortality are consequences of progressive locoregional effects within the peritoneal cavity. The first reported case was in the early 20th century, however, due to the rare nature of the disease and a large gap in understanding of the clinicopathological effects, the next reported MPM cases were only published half a decade later. Since then, there has been exponential growth in our understanding of the disease, however, there are no prospective data and a paucity of literature regarding management. Traditionally, patients were treated with systemic therapy and the outcomes were very poor, with a median survival of less than one year. However, with the advent of cytoreductive surgery and locoregional chemotherapy, there have been significant improvements in survival. Even more recently, with an improved understanding of the molecular pathogenesis of MPM, there have been reports of improved outcomes with novel therapies. Given the disastrous natural history of MPM, the limited data, and the lack of universal treatment guidelines, an in-depth review of the past, present, and future of MPM is critical to improve treatment regimens and, subsequently, patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.